|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, September 26, 2017 ) The report "Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021", This report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global cancer immunotherapy market along with the estimates and forecasts of the revenue and market share analysis. Factors such as increasing incidence of cancer and rising healthcare expenditure are driving the growth of this market.
Browse 42 market data Tables and 68 Figures spread through 140 Pages and in-depth TOC on "Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021"
Early buyers will receive 10% customization on reports.
Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=197577894
In this report, the global cancer immunotherapy market has been segmented based on type, application, end user, and region. On the basis of type, the market has been segmented into monoclonal antibodies, cancer vaccines, checkpoint inhibitors, and immunomodulators. The monoclonal antibodies segment is expected to account for the largest share of the market in 2016, while the checkpoint inhibitors segment is projected to witness the highest CAGR from 2016 to 2021. The high growth in this segment is primarily attributed to the high success rate of these inhibitors.
On the basis of applications, the global cancer immunotherapy market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and others. The lung cancer segment is expected to grow at the highest CAGR during the forecast period. The high growth in this segment can be attributed to the increasing prevalence of this type of cancer and rising demand for advanced treatment options.
Get Free Report Sample Pages: http://www.marketsandmarkets.com/requestsample.asp?id=197577894
On the basis of end users, the global cancer immunotherapy market is segmented into hospitals and clinics & others. The hospitals segment is expected to account for the largest share of the global cancer immunotherapy market in 2016. The rise in healthcare spending has resulted in the increasing use of immunotherapeutic drugs in hospitals.
Based on regions, the global cancer immunotherapy market is segmented into North America, APAC, Europe, and the Rest of the World (RoW). North America is expected to account for the largest share of the market in 2016. Growth in this regional segment is driven by factors such as increase in patient pool and initiative taken by the government for the development of cancer immunotherapy.
Key players in the cancer immunotherapy market include Amgen (U.S.), AstraZeneca (U.K.), F. Hoffmann-La Roche AG (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb (U.S.), Eli Lilly and Company (U.S.), Janssen Global Services, LLC (Belgium), Merck (U.S.), Novartis (Switzerland), and Pfizer (U.S.).
MarketsandMarkets
Mr. Rohan
1-888-600-6441
sales@marketsandmarkets.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
